Lv41
690 积分 2022-11-14 加入
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study
3小时前
待确认
[(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
8天前
已完结
Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity
10天前
已完结
根治性膀胱切除尿流改道术中国膀胱癌联盟共识
18天前
已完结
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin
22天前
已完结
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin
22天前
已关闭
Association between family functioning and delay in seeking medical care of Chinese bladder cancer patients: the mediating effect of coping styles
28天前
已完结
Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer
1个月前
已关闭
[(177)Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases
1个月前
已完结
Real-world evaluation of [(177)Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort
1个月前
已完结
皖公网安备34019202002308
